Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
China Unveils the Final Drug List for the 7th Volume-based Procurement (VBP) On July 18, China announced the official list of 327 products for the 7th volume-based procurement (VBP).The 327 products are owned by 217 bid-winning companies, which will supply the products to public health institutions. Among the companies, 6 are international enterprises—Hetero Labs, Bracco Sine, Almirall, Sandoz, and Pfizer.
Jul 25, 2022
327 Drug Products to Enter China's 7th Round of Volume-based Procurement (VBP) Six international pharma companies--Hetero Labs, Bracco Sine, Almirall, Sandoz, Astellas, and Pfizer--won the bid in the preliminary result of the China's 7th round of volume-based procurement (VBP) of drugs.
Jul 15, 2022
China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs On June 20, China National Joint Drug Procurement Office announced the start of the 7th round of volume-based procurement (VBP), covering 59 drugs with different active pharmaceutical ingredients.
Jun 24, 2022
Law & Regulation Marketing Approval Volume-Based Procurement Medical Insurance Innovative Drug Cancer Cardiovascular Disease Rare Disease Drug Registration New DrugChina's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
China's Insulin VBP Sees Average Price Cut of 48.75% China’s insulin VBP (volume-based procurement)--eleven drug makers won the bid to supply insulin products to public healthcare institutions across China. Among 42 bid-winner products, Novo Nordisk took the champion with seven products. Two local Chinese companies—Gan & Lee and the United Laboratories—took the second and third places with six products respectively.
Dec 06, 2021
A Record Number of Foreign Companies Win Bidding for China's 5th VBP of Drugs 251 products from 148 companies won the bidding on June 23 in Shanghai for the latest and fifth round of China’s national centralized drug procurement. The bidding saw some record numbers. One of them is the unprecedented number of 10 international pharma companies successfully earning places in the procurement program.
Jun 30, 2021
China's 2021 Two Sessions: What Can We Expect for the Medical and Health Sectors? Chinese Premier Li Keqiang pointed out nine major objectives in the medical and health sectors in 2021 in the Government Work Report on March 5th.
Mar 15, 2021
China to Carry out National Insulin Procurement China will pilot a nationwide insulin procurement which may refer to the previous pilot insulin procurement scheme in Wuhan. It means the price of insulin products will be significantly reduced, and the market share of relevant pharmaceutical companies in China will be affected.
Mar 08, 2021
Chinese Market Becomes More Intense for Antidiabetic Drugs China's fourth round of national centralized drug procurement has begun, according to the Jinfu Chen, deputy head of the National Healthcare Security Administration in Beijing on Jan. 29, 2021. This time five new diabetes medications are included in the procurement list. They are empagliflozin, canagliflozin, repaglinide, nateglinide, and gliclazide.
Mar 08, 2021
- China CDE Q&A | Drug Registration Applications & Clinical Trials
- How to Sell OTC Drugs to China via Cross-Border E-Commerce
- China's First Homegrown COVID-19 Pill, Azvudine, is Priced at 270 Yuan Per Bottle
- Monthly Report: New Drug Approvals in China | July 2022
- Monthly Report: New Drug Approvals in China | August 2022